Scientific Reports · 2022 · 13 citations · 29 references
MedicineOncologySurgeryChemotherapyOncologic SurgerySurgical OncologyHepatocellular CarcinomaLiver CancerSupportive Care In CancerTumor Resection TechniquesCombination TherapyHazard Ratio ModelingHepatocellular Carcinoma ResectionHepatocellular Carcinoma TreatmentNon-surgical TherapyOptimal Treatment RegimesOverall MortalityTreatment Modality Selection
We investigated the outcomes of patients with ruptured hepatocellular carcinoma (HCC) and identified the optimal treatment modality for such patients. We retrospectively enrolled 91 patients with treatment-naive HCC and tumor rupture at diagnosis, including 38 patients who underwent surgical resection (SR) alone, 28 patients who were treated with transarterial chemoembolization (TACE) only, 20 patients who had a sequential combination therapy of TACE and SR, and 5 patients who received best supportive care. After a median follow-up of 13.1 months, 54 patients died. The cumulative 5 years overall survival (OS) rates were 55.1% and 0% in the SR group and non-SR group, respectively (p < 0.001). Non-SR therapy was associated with poorer OS according to a multivariate analysis with a hazard ratio of 6.649 (95% confidence interval 3.581-12.344, p < 0.001). Moreover, whether patients received TACE or not did not impact the OS in both the SR group and the non-SR group. In conclusion, for patients with HCC and tumor rupture at the time of diagnosis, SR could lead to better prognoses than non-surgery treatment modalities. Moreover, a sequential combination of TACE and SR had similar clinical outcomes when compared to SR alone.
29
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Severin Gloor, Kai Oliver Jensen, Stefan Breitenstein et al. · Case Reports in Gastroenterology · 2017 · 5.4K citations · Full text